Lapatinib, an oral small-molecule tyrosine kinase inhibitor (TKI) of both HER2 and EGFR, thus confers a significant survival benefit in HER2-positive breast cancer patients when combined with capecitabine or paclitaxel [17,18]. Here, ERBB2 is linked to breast cancer.